Our Research

Discover our recent findings, catch up with news, and review in-depth resources and case studies.

Connect with Resolian at these upcoming events.

Resolian Acquires China-Based Bioanalytical CRO Denali Medpharma

Resolian, a global bioanalytical contract research organization (CRO) specializing in drug metabolism and pharmacokinetics for small and large molecules, has acquired Denali Medpharma…
Read more

How to Build a Comprehensive Response to Client Needs as a CRO

As a CRO, meeting client expectations can be an ongoing challenge. What can organizations do to make sure their research is as effective and efficient as possible?
Read more

Pharmacokinetics – Area Under the Curve Calculations

The area under the concentration vs. time curve is a useful description of exposure of drug following administration. There are different ways in which AUC may be calculated…
Read more

Introduction to Pharmacokinetics

An understanding of the characteristics of drug exposure following administration and how it relates to safety and efficacy is critical for progressing drug development (e.g. in decision making for drug candidates…
Read more

The Role of OGNTs in the Personalized Medicine Revolution

This paper highlights oligonucleotides (OGNTs) as a revolutionary new class of drugs in personalized medicine due to their targeted approach to genetic diseases.
Read more

Single-Day Protein LC-MS Bioanalysis

This paper explains how next-generation trypsins offer faster protein digestion for LC-MS analysis with comparable performance to standard methods.
Read more
Scroll to Top

Resolian Opens Expanded State-of-the-Art Analytical Laboratory in Fordham

June 29, 2023

Resolian, a global leader providing bioanalytical, DMPK, and CMC testing services in the pharmaceutical and biopharmaceutical industry, has opened its 440m² analytical laboratory in Fordham, Cambridgeshire, UK.

The new analytical lab, which the company announced plans for earlier this year, provides a 30% larger lab to help meet the rising demand for analytical and materials science work.

“We are delighted to have expanded our lab at Fordham by over 30% to meet the growing demand.” said Analytical Sciences Operations Director Ellen Stokvis. “Our new state-of-the-art purpose-built lab further strengthens our analytical and materials science capabilities. Increasing lab space from 330m² to 440m² enables more companies to be able to work with us.

“The new laboratory space has been designed to support better collaboration and improved workflow and traffic flow and alongside our Sandwich site, this investment in the analytical and materials science area of our business means we are set up and ready to support our customers demand now and in the future.”

Zhiyang Zhao, Ph.D.

Chief Scientific Officer

Linkedin

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade. 

Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia. 

 

Patrick Bennett

Chief Executive Officer

Linkedin

Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now Chief Business Officer at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD. 

Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.